<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 159 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page158.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=159">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 159 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 159</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=159"><img src="../thumb/159.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>128 / 2020-04                                                    Cardio-Vascular Agents - 7.7.1 / 7.7.2
   Special precautions: Hypoalbuminaem.states, reduc.concom.anti-  pain, malaise, periph.oed., cholestat.jaund., hepatit., allerg. reacts.   CV complic.prevent: Dos.range: 10-80 mg once dly.
   coag.dos., monit.triglycer./tot. cholester.& HDL lev.3x dur.1st 8 wks.&   incl.anaphylax., infect., flu syndr., sinusit., liv.funct.abnorm., weight   Contraindications: Act.liv.dis., persist.unexpl. elev. ser.transaminas.
   discont.if no signif.triglycer.& tot.cholester.reduct., pts.to consult dr.if   gain, hypo.-/hyperglycaem.,arthralg., musc.cramps, myosit., head-  exceed.3x ULN, concom. diltiazem/rifampicin/grapefruit juice, Child-
   musc.pain/tendern./weakn.develop, 2 hr.interv.betw. cholestyramine   ache, insomn.,dizzin., paraesthes., hypoaesthes., periph.neuropa-  Pugh B & C, pregn., breastfeed., women of childbear. potent.unless
   & bezafibrate admin.         thy, amnes., impot., skin rash, prurit., alopec, Stev.John. syndr/tox.   adeq.contracept., lact.intol.
   Drug interactions: Cholestyramine imp. absorpt., poss.interact.with   epiderm.necrolys./erythema multiform., urticar.  Side effects: Rhabdomyolys.with/without ren. impairm., flu-syndr.,
   oral coumar.anti-coagul., act.of insul.& sulphonylureas poss. potent.  Special precautions: Lipid lower.ther.to be component of multipl-  headache, accid.inj., GI disturbs., back/chest pain, myalgia, arthralg.,
   LOPID, Pfizer [P/S]          risk-fact.intervent.where atherosclerot. vasc.dis.risk pres., lipid alter.  allerg. reacts. incl.anaphylax., asthen., sinusit., pharyngit., skin reacts.
                                agents used in addit.to diet restrict.in saturat.fat & cholesterol only
                                                              incl.Stev.Johns.syndr./tox. epiderm. necrolys./erythem.multiforme,
   Gemfibrozil.                 when response to diet & other non-pharmacological meas.inadeq.,   bld. dyscras., tinnit., pancreatit., malaise, periph.oed., fatig., hepatit.,
   Indications: Adjunct.to diet & weight loss in Fredrickson Type IIb   excl.second. caus.prior to init.ther. & meas.lipid prof., LFT bef. init.  cholestat. jaund., tendon rupt., hyper./-hypoglycaem., anorex., weight
   (mix.hyperlipidaem.) & Type IV hyperlipidaem.  ther./aft.each dos.incr./period.thereaft., incr. transaminas.lev.should   gain, CNS eff., dizzin., periph.neuropathy, dysgeus., hypoaesthes., par-
   (S3) TABS, [P/S] Y/7.5/245.  be monit.unt.stable, withdr. ther.if ALT/AST incr.&gt; 3x ULN persist, sub-  aesthes., myosit., musc.cramps, myopathy, insomn., impot., alopec.,
   788627-007: 600 mg, 60, R621,46  stant. alcoh.consum., liv.dis.hist., discont.if CPK lev.are marked.elev.or   immune mediat. necrotis.myopathy.
   Dosage: 1 200 mg dly in 2 div.dos.30 min.bef. morn. & even. meals.   if myopathy is diagn./ susp., report unexpl.musc.pain/tender./weakn.   Warnings and special precautions: Inform.pts. of potent.hazards
   900 mg dly. in 2 div.dos.may prove suffic.in cases of intol.at norm.dos.   esp. if accomp.by fev./malaise, withdr.in risk fact. predispos.to ren.fail.  to foet., monit.liv.funct. bef.init. ther.& per.as clinic.indic., withdr.ther.
   Max. 1 500 mg dly.in div.dos. Withdraw aft.3 mnths.if respon. inadeq.  developm.second.to rhabdomyolys, monit.concom.digoxin/warfarin,   in case of ser. liv.inj. with clinic.sympt.&/hyperbilirubinaem./ jaund.,
   Contraindications: Hepat./sev.ren.dysfunct.incl. prim. bil.cir-  1 mnth. interv.betw.discont.ther.& concept.in event of plann.pregn.  heavy alcoh.ingest.&/ liv.dis.hist., monit. with digoxin/OC’s/warfar./
   rhos., pre-exist.gallbladd.dis., concom. repaglinide/ simvastatin/  Drug interactions: Myopathy risk incr.with concom. immunosup-  fusidic acid, concom. colchicine, avoid grapefruit juice, report.unexpl.
   dasabuvir/selexipag          press.agents incl.cyclospor./ fibric acid derivat./nicotin.acid/azole   musc. pain./tend./weakn.esp.if accomp.by fev./ malaise, discont.ther.
   Side effects: GI disturbs., headache, fatig., eczema, rash, dermatit.,   antifung.or erythromycin & cytochrome P450 inhibits., poss. incr.   if CPK lev.are marked.elev.or myopathy is diagn./susp., withdr.in ac./
   prurit., urticar., vertigo, impot., myosit., myalg., ac.appendicit., atrial   plasma conc.with protease inhibits., incr.AUC with diltiazem HCl,   ser.condit. suggest.of a myopathy/having a risk fact. predispos. to ren.
   fibrillat., blurr.vis., depress., paraesthes., arthralg., cholestat. jaund.,   poss.incr.plasma conc.with grapefruit juice, poss.reduct.in plasma   fail. developm.second.to rhabdomyolys., avoid concom.telaprevir/ti-
   pancreatit., dizzin., somnol., periph. neurit., synovit., myopathy,   conc.with cytochrome P450 3A4 induc., oral antacids contain Mg   pranavir plus ritonavir, concom.protease inhibits.combinat., excl. sec-
   myasthen., painf. extremit., exfoliat.dermatit., decr.libido, angio-/   & Al decr.plasma conc., plasma conc.decr. with colestipol although   ond.caus.& perf.lipid profile bef.init.ther., lipid low.ther.to be comp.
   laryng.oed., rhabdomyolys., photosens., bld. dyscras., alopec., chol-  LDLC reduct.was great.in combin.than when either med was giv.  of multip.risk-fact.interv. where artherosclerot. vasc.dis.pres., lipid
   ecystit., cholelithias.      alone, digox. steady-state plasma conc.incr., incr.plasma conc.with   alter. agents to be used in addit.to diet restrict.in satur. fat & cholestr.
   Warnings and special precautions: Safety in pregn./ lactat &   erythromyc.a known cytochrome P450 3A4 inhibit., AUC values of   only when respons.to diet & non-pharmacolog. meas.been inadeq.,
   childr.not est., only for pts.with a potent.responsive lipid/lipoprot.  norethindrone & ethinyl estradiol incr.  temp.susp.with concom. fusid.acid ther., incr.haemorrh.stroke risk in
   abnormal.where appropr.diet.ther.alone insuffic., diabet., cholelith-  See also MDR page 52.  pts.who had haemorrh.stroke/TIA with.preced. 6 mnths., concom.ri-
   ias., discont.in case of gallstone dev., monit. bld.counts/lipid prof.   fampicin not recomm., limit. exper.in paed.pts.with sev.dyslipidaem.
   & liv.funct.periodic., admin. bile-acid binding resins 2 hrs apart from   ADCO-SIMVASTATIN, AI Pharm Ltd [P/S]  Drug interactions: Myopathy risk incr.with concom.immunosup-
   gemfibrozil., concom.warfarin/CYP2C8 substrates.  Simvastatin.  press.agents/fibric acid derivat./ niacin/cytochrome P450 3A4 in-
   Interactions: Sev.myosit.with mark.elev.creatine kinase & rhabdo-  Indications: Reduct.of elev.tot.cholester.& LDL-cholester.in prim. hy-  hibits., poss. incr.plasma conc.with concom.cytochrome P450 3A4
   myolys.with concom.HMG-CoA reductase inhibit, incr.prothromb.  percholesterolaem.when respons. to diet & other nonpharmacolog.
   time with concom. coumar.anticoags, reduc.bioavail.with bile-acid   meas. inadeq.,  reduc.coron.death/non-fat.MI/risk for undergo.myo-  inhibits., poss.incr.bioavail.with OATP1B1 inhibit.e.g.ciclosporin,
                                                              steady-state plasma conc.of digox.incr., AUC values of norethindrone
   bind.resins, incr.expos.of concom.meds. metabolis. by CYP2C8, incr.  card.revasculat.proced.& slow. coron.artheroscleros.progress in pts.
   risk of sev. hypoglycaem. with repaglinide, incr.risk of QT prolongat.   with est. coron. heart dis.& hypercholesterolaem. unrespons. to diet.  & ethinyl estradiol incr., poss. myopathy with colchicine, poss.incr.
                                                              AUC & C max with itraconazole, grapefr.juice poss.inhib. CYP 3A4 & incr.
   with dasabuvir, incr.risk of seiz.with enzalutamide, risk of neuromusc.  (S4) TABS. 35/7.5/0277,0278,0279
   tox./ rhabdomyolys. with concom.colchicine.  701276-003: 10 mg, 30, R33,60  plasma conc., decr.plasma conc.with oral antacids cont. Mg & Al, sev.
                                                              musc.probl.incl. rhabdomyolys. with fusid.acid, incr.plasma conc. with
   SANDOZ BEZAFIBRATE 400, Sandoz [P/S]  701279-003: 20 mg, 30, R34,80  protease inhibits./erythromycin, incr.AUC with diltiazem HCl, plasma
   Bezafibrate.                 701281-003: 40 mg, 30, R37,13  conc.decr.with colestipol although LDL-C reduct.was great.in com-
                                Dosage: Cholester.-low.diet prior to & dur.treatm.
   Indications: Prim.hyperlipidaem.type IIa, IIb, III, IV & V, second.  bin. than when either med was giv.alone., reduc. plasma conc.with
   hyperlipidaem.               Hypercholesterolaem: 10 mg/day in even. Adjust dos.if reqd.,   cytochrome P450 3A4 induc.
                                at interv.of not less than 4 wks., to a max.of 40 mg/day in even.
   (S3) TABS. 29/7.5/0435.                                    See also MDR page 591.
   828300-003: 400 mg, 30, R245,21`  Coron.heart dis: 20 mg/day in even. Adjust dos. as above if reqd.  ASPEN PRAVASTATIN, (Aspen Pharmacare: Pharma)
                                Concom.ther: Bile acid sequestr: Admin.1 hr. bef./ 4hrs.aft.
   Dosage: 200 mg 3xdly with/aft. food.
   Maint: 400 mg dly.           cholestyramine.               Pharmacare [P/S]
                                Contraindications: Ac.liv.dis., unexplain. persist. ser.transaminas.
                                                              Pravastatin sod.
   Contraindications: Pregn., lactat., sev.ren. dysfunct., liv.dysfunct.,
   prim.bil.cirrhos., gallston. & gall-bladd.disords., nephrot.syndr., dialys.  elev., porphyr., pregn. & lactat., female pts.of child-bear.potent., safety   Indications: In combinat.with diet to decr. elev. ser.tot.cholesterol
                                                              & LDL cholesterol in prim. hypercholesterolaem./ heterozyg.familial
                                & effic.in paed. pts.not est.
   with ren.dysfunct., MAOI with hepatot.potent.
   Side effects: GI disords., mass gain, CNS eff., skin rash, alopec., im-  Side effects: GI disturbs., CNS effs., skin reacts., prurit., bld.dys-  hypercholesterolaem/ mix.hyperlipidaem.when respons.to diet/ other
                                                              non pharmacolog.meas. alone not adeq., to reduc.tot.mortality by re-
                                cras., alopec., myalg., paraesthes., blurr.vis., rhabdomyolys., hep-
   pot., bld.dyscras., myosit.-like pains or musc.weakn., CV disords incl.
   card. arrhythm., cholecystit., gallstones, pancreatit.  atit., jaund., pancreatit., myopathy, mass gain, periph. neuropathy,   duc. coron. death/reduc.risk of non-fat.MI/ reduc.risk of undergoing
                                                              myocard. revascularizat.proced.& slow.progress.of coron. athero-
                                hypersens.reacts.
   Special precautions: Adjust dos.accord.to ser. creatinine lev.in
   ren.insuffic., monit.liv.funct.& triglycer.lev.3xdur.1st 8 wks.(discont.  Special precautions: Not effect.in homozygous  famil. hypercho-  scleros.in pts. with CHD & hypercholesterolaem.unrespons.to diet.
                                                              (S4) TABS, 38/7.5/0123, 0139, 0140
                                lesterolaem./hypertriglyceridaem., concom.immunosuppress./fibric
   if no signific. reduct.), with cholestyramine 2 hrs.interv.betw. medic.
   Drug interactions: Cholestyramine imp.absorpt., poss.dos.reduc.  acid derivat./ niacin with HMG-CoA-reduct.inhibit.result.in rhabdo-  705212-001: 10 mg, 30, R217,00
                                                              705213-001: 20 mg, 30, R277,09
                                myolysis, liv.funct.tests.recomm.bef. start. treatm.& period.thereaft.,
   with coumarin, act.of insul.& sulphonylureas poss.potent.
                                substant.alcoh. consumpt., liv.dis.hist., monit.for myopathy & discont.   705214-001: 40 mg, 30, R323,68
                                if myopathy occurs/suspect., withdr. tempor .in pts receiv.cyclospor.if   Dosage: In combinat.with cholesterol-low. diet. Is effect.in combinat.
                                system.azole derivat.antifung.reqd., with concom.coumar. anticoags.   with bile acid sequestrants.
   7.7.2   HMG-CoA reductase    monit.prothrom.lev.when init.ther.& dur.early ther.  Adults:
                                Drug interactions: Anticoag.eff.of coumar. anticoags. potent., di-
                                                              Hypercholesterolaem: 10 mg/day as sngl. even. dos. Reduc.if
          inhibitors (Statins)  goxin lev.incr., propranolol decr.mean max.conc., mibefradil incr.conc.  LDL-cholesterol falls bel. 1,94 mmol/L or tot.plasma chol. lev. fall
                                                              bel.3,6 mmol/L
   ADCO-ATORVASTATIN (MDR Listing)  ASPAVOR, Pfizer [P/S] &   Cor.heart dis: Init.20 mg/day as sngl.even.dos.
                                Atorvastatin
   ASPAVOR (MDR Listing)                                      If necess.adjust dos.at interv.of not less than 4 wks. up to max.80 mg/
                                Indications: Adjunct.to diet for reduc.of elev.tot.-cholester., LDL-cho-  day as sngl. even.dos.
   ADCO-ATORVASTATIN, AI Pharm Ltd [P/S] &  lester., apolipoprot.-B & triglyceride lev. & to mod.incr.HDL-cholester.  Contraindications: Other HMG-CoA reduct. inhibit.hypersens., ac./
   Atorvastatin.                lev.in prim. hypercholesterolaem.(heterozygous famil.& non-famil.  chron. liv.dis., unexplain. persist. elev.ser. transaminas., pregn.& lac-
   Indications: Adjunct.to diet for reduc.of elev.tot.-cholesterol, LDL-  hypercholesterolaem.) & combin./mix. dyslipidaem., reduc.tot.-C &   tat., women of child bear.potent., safety in porphyr. not est., safety &
   cholestrol, apolipoprot.-B & triglyceride lev.in prim.hypercholesterol-  LDL-C in homozygous familial hypercholesterolaem.as adjunt.to other   effic.in paed.pts.not est.
   aem./mix. dyslipidaem., heterozygous familial hypercholesterolaem.,   lipid low.treatm.or if such treatm. unavail., in paed. pts. 10-17 yrs.as   Side effects: Myalg., musc.cramps, skin rash, alopec., CNS effs.,
   reduc.tot.-C & LDL-C in homozygous familial hypercholesterolaem.as   adjunct.to to diet reduc.total-C, LDL-C & apo B lev.in boys/postmen-  periph. neuropathy, myopathy, myosit., rhabdomyoloys., hypersens.
   adjunt.to other lipid low. treatm.or if such treatm.unavail.  arch.girls with heterozyg.famil.hypercholesterolaem.if aft.adeq. diet   reacts., GI disturbs., pancreatit., mass gain, anaem., neutropen.
   (S4) TABS, 43/7.5/1116, 1117, 1118  ther.trial foll.pres: LDL-C remain.≥ 4,98 mmol/L (190 mg/dL) or LDL-C   Special precautions: Act.metabol.fetotox.& teratogen.in rats, max.
   718073-001: 10 mg, 30, R33,73  remain.≥ 4,04 mmol/L (160 mg/dL) and posit.fam.hist.of prem.CV dis./   dos. 10 mg/day recomm. with concom. cyclospor./fibrates/lipid low.
   718074-001: 20 mg, 30, R36,09  2 or more other CVD risk fact.pres, CV complic. prevent.reduc.risk of   niacin dos., monit.INR bef.init.& reg.dur.concom. anticoag. ther., ad-
   718075-001: 40 mg, 30, R62,40  ischaem.CV & cerebrovasc. dis.where no clinic.evid.of CV dis.& with/   min.1 hr.bef./4 hrs.aft. cholestyramine, sev.ren.insuffic., subst. alcoh.
   Dosage: Init.& contin.diet ther.bef.& dur.treatm. Init.10 mg once dly.   -out dyslipidaem.but with multipl.CHD risk fact. second.prevent.of CV   ingest., liv.dis.hist., predisposit.to ren.fail. second. to rhabdomyolysis,
   Dos.indiv.accord.to baseline LDL-C lev.& pt.respons. Adjust dos.only   events prev.in pts.with clinic. evid.CHD & incr.cholestr.lev.  monit. liv.funct.bef. init. ther.& reg.dur.ther.discont.if rise in transami-
   aft.4 wks. or more. Max.recomm.dos: Depend.on indicat.  (S4) TABS. A39/7.5/0017, 0018, 0019, 43/7.5/0837  nase lev.persist./incr.3x or more of upper limit of norm., pt.to report.un-
   Prim.non-famil.hypercholesterolaem.& combin. (mix.) hyper-  708121-001: 10 mg, 30, R34,02  explain. sympts. indicat. myopathy, discont.ther.if myopathy diagnos./
   lipidaem: 10 mg once dly. Therap.response within 2 wks.& max.  708122-001: 20 mg, 30, R36,13  suspect., concom.cyclospor./ itra-/ketoconazole/erythro-/clarithromy-
   respons usual. achiev.within 4 wks. Respons.maint.dur. chron.ther.  710912-001: 40 mg, 30, R63,59  cin/HIV prot. inhibit.& nefazodone not recomm., discont. ther.tempor.
   Heterozygous familial hypercholesterolaem: Init.10 mg once   720211-001: 80 mg, 30, R115,08  in pts.receiv.cyclospor.if system. azole antifung.ther.reqd., lact.intol.
   dly. Dos.indiv.& adjust.every 4 wks. up to 40 mg dly. Thereaft.bile   Dosage: Cholest.-low.diet bef.init.& dur.ther. 10 mg once dly. Indiv.  Drug interactions: Incr.plasma lev.with meds. that inhibit.cyto-
   acid sequestrant eg colestipol maybe combin.  accord.to basel.LDL-C lev., therap.goal, pt.respons. Adjust dos.only   chrome P450 isoenzyme CYP3A4 (e.g. cyclospor./itra-/ketoconazole/
   Homozygous familial hypercholesterolaem: Adults: Most pts.  aft. 4 wks.or more. Max.recomm.dos: Depend.on indic.  erythro-/clarithromycin/HIV prot.inhibit.& nefazodone) incr. myopathy
   respond to 80 mg.Limit.exper.in childr.  Prim. hypercholesterolaem.& combin.(mix.) hyperlipidaem:   risk, incr.myopathy risk.with other meds. known to cause myopathy
   Contra-indications: Act.liv.dis./persist.unexpl. elev. ser.transami-  10 mg once dly. Therap.respons. evid.within 2 wks.& max.respons.  (e.g fibrates & niacin), digox.lev.incr., anticoag.eff.of coumar. antico-
   nas., pregn.& lactat., women of childbear. potent.unless contracept.  achiev.with. 4 wks. & maint. dur.chron.ther.  ags. poss.incr., cholestyramine decr. bioavail.
   adeq., concom. rifampicin/diltiazem & grapefruit juice, Child-Pugh   Heterozygous famil.hypercholesterolaem: Paed.pts. (&gt; 10-
   B & C (liv.cirrhosis),       17 yrs): Init.10 mg/day with max. recomm.dos. 20 mg/day.  ASPEN SIMVASTATIN, (Aspen Pharmacare: Pharma)
   Side-effects: Rhabdomyolys., myalg, myopathy, thrombocyto-  Homozygous famil. hypercholesterolaem: Adults: Most pts.  Pharmacare [P/S]
   paen., tinnit., GI disturbs., pancreatit., asthen., abdom./back/chest   respond to 80 mg.  Simvastatin.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page158.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page154.html">154</a>&nbsp;&nbsp;&nbsp;<a href="page155.html">155</a>&nbsp;&nbsp;&nbsp;<a href="page156.html">156</a>&nbsp;&nbsp;&nbsp;<a href="page157.html">157</a>&nbsp;&nbsp;&nbsp;<a href="page158.html">158</a>&nbsp;&nbsp;&nbsp;<a href="page159.html">159</a>&nbsp;&nbsp;&nbsp;<a href="page160.html">160</a>&nbsp;&nbsp;&nbsp;<a href="page161.html">161</a>&nbsp;&nbsp;&nbsp;<a href="page162.html">162</a>&nbsp;&nbsp;&nbsp;<a href="page163.html">163</a>&nbsp;&nbsp;&nbsp;<a href="page164.html">164</a>
             </td>
             <td width="35%"><a href="page160.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page160.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
